Zobrazeno 1 - 10
of 589
pro vyhledávání: '"Larson, KB"'
Autor:
Cammarata AP; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Safir MC; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Trang M; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Larson KB; Entasis Therapeutics, Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA., O'Donnell JP; Entasis Therapeutics, Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA., Bhavnani SM; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA., Rubino CM; Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Nov 21, pp. e0048524. Date of Electronic Publication: 2024 Nov 21.
Publikováno v:
Adolescent Health, Medicine and Therapeutics, Vol 2013, Iss default, Pp 79-87 (2013)
Kajal B Larson, Jennifer R King, Edward P Acosta Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA Abstract: Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US
Externí odkaz:
https://doaj.org/article/aa6e7c3420174bf3adad7383ca819bcf
Autor:
Arrieta AC; Pediatric Infectious Disease, Children's Hospital of Orange County, Orange, California., Ang JY; Pediatric Infectious Disease, Children's Hospital of Michigan, Detroit, Michigan.; School of Medicine, Wayne State University, Detroit, Michigan., Zhang Z; Merck & Co, Inc., Kenilworth, New Jersey., Larson KB; Merck & Co, Inc., Kenilworth, New Jersey., Yu B; Merck & Co, Inc., Kenilworth, New Jersey., Johnson MG; Merck & Co, Inc., Kenilworth, New Jersey., Rhee EG; Merck & Co, Inc., Kenilworth, New Jersey., Feng EH; Merck & Co, Inc., Kenilworth, New Jersey., Rizk ML; Merck & Co, Inc., Kenilworth, New Jersey.
Publikováno v:
Pediatric pulmonology [Pediatr Pulmonol] 2020 Aug; Vol. 55 (8), pp. 2025-2032. Date of Electronic Publication: 2020 May 18.
Autor:
Boix V, Fedorak RN, Mullane KM, Pesant Y, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, Murata Y
Publikováno v:
Open forum infectious diseases
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Although the incidence of Clostridium difficile infection (CDI) is increasing, available CDI treatment options are limited in terms of sustained response after treatment. This phase 3 trial assessed the efficacy and safety of surotomycin, a novel bac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6e6eabed4f42a0c9ce5c2213602c840f
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2019
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2019
Autor:
Nicolau DP; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA., De Waele J; Ghent University Hospital, Gent, Belgium., Kuti JL; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA., Caro L; Merck & Co., Inc., Kenilworth, New Jersey, USA., Larson KB; Merck & Co., Inc., Kenilworth, New Jersey, USA., Yu B; Merck & Co., Inc., Kenilworth, New Jersey, USA., Gadzicki E; Merck & Co., Inc., Kenilworth, New Jersey, USA., Zeng Z; Merck & Co., Inc., Kenilworth, New Jersey, USA., Rhee EG; Merck & Co., Inc., Kenilworth, New Jersey, USA., Rizk ML; Merck & Co., Inc., Kenilworth, New Jersey, USA. Electronic address: matthew_rizk@merck.com.
Publikováno v:
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Apr; Vol. 57 (4), pp. 106299. Date of Electronic Publication: 2021 Feb 07.
Autor:
Caro L; Merck & Co., Inc., Kenilworth, NJ, USA., Nicolau DP; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA., De Waele JJ; Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium., Kuti JL; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA., Larson KB; Merck & Co., Inc., Kenilworth, NJ, USA., Gadzicki E; Merck & Co., Inc., Kenilworth, NJ, USA., Yu B; Merck & Co., Inc., Kenilworth, NJ, USA., Zeng Z; Merck & Co., Inc., Kenilworth, NJ, USA., Adedoyin A; Merck & Co., Inc., Kenilworth, NJ, USA., Rhee EG; Merck & Co., Inc., Kenilworth, NJ, USA.
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Jun 01; Vol. 75 (6), pp. 1546-1553.
Autor:
Larson KB; Merck & Co, Inc., Kenilworth, New Jersey, USA., Patel YT; Cognigen Corporation, Buffalo, New York, USA., Willavize S; Cognigen Corporation, Buffalo, New York, USA., Bradley JS; University of California, San Diego, California, USA.; Rady Children's Hospital, San Diego, California, USA., Rhee EG; Merck & Co, Inc., Kenilworth, New Jersey, USA., Caro L; Merck & Co, Inc., Kenilworth, New Jersey, USA., Rizk ML; Merck & Co, Inc., Kenilworth, New Jersey, USA matthew_rizk@merck.com.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 May 24; Vol. 63 (6). Date of Electronic Publication: 2019 May 24 (Print Publication: 2019).
Autor:
Bradley JS; From the Rady Children's Hospital San Diego, San Diego, CA.; University of California San Diego, La Jolla, CA., Ang JY; Children's Hospital of Michigan, Detroit, MI.; Wayne State University, Detroit, MI., Arrieta AC; Children's Hospital of Orange County, Orange, CA., Larson KB; Merck & Co, Inc., Kenilworth, NJ., Rizk ML; Merck & Co, Inc., Kenilworth, NJ., Caro L; Merck & Co, Inc., Kenilworth, NJ., Yang S; Merck & Co, Inc., Kenilworth, NJ., Yu B; Merck & Co, Inc., Kenilworth, NJ., Johnson MG; Merck & Co, Inc., Kenilworth, NJ., Rhee EG; Merck & Co, Inc., Kenilworth, NJ.
Publikováno v:
The Pediatric infectious disease journal [Pediatr Infect Dis J] 2018 Nov; Vol. 37 (11), pp. 1130-1136.
Publikováno v:
Clinical Pharmacology & Therapeutics; Jan2015, Vol. 97 Issue 1, p66-78, 13p
Autor:
Daley P; Memorial University of Newfoundland, St John's, Newfoundland, Canada., Louie T; University of Calgary, Calgary, Alberta, Canada., Lutz JE; St Charles Health System, Bend, OR, USA., Khanna S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Stoutenburgh U; Merck & Co., Inc., Kenilworth, NJ, USA., Jin M; Merck & Co., Inc., Kenilworth, NJ, USA., Adedoyin A; Merck & Co., Inc., Kenilworth, NJ, USA., Chesnel L; Merck & Co., Inc., Kenilworth, NJ, USA., Guris D; Merck & Co., Inc., Kenilworth, NJ, USA., Larson KB; Merck & Co., Inc., Kenilworth, NJ, USA., Murata Y; Merck & Co., Inc., Kenilworth, NJ, USA.
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2017 Dec 01; Vol. 72 (12), pp. 3462-3470.